0001213900-24-061184.txt : 20240715
0001213900-24-061184.hdr.sgml : 20240715
20240715091612
ACCESSION NUMBER: 0001213900-24-061184
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20240715
DATE AS OF CHANGE: 20240715
EFFECTIVENESS DATE: 20240715
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: NLS Pharmaceutics Ltd.
CENTRAL INDEX KEY: 0001783036
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-518686
FILM NUMBER: 241115984
BUSINESS ADDRESS:
STREET 1: THE CIRCLE 6
STREET 2: 8058
CITY: ZURICH
STATE: V8
ZIP: CH-6370
BUSINESS PHONE: 41-41-618-80-00
MAIL ADDRESS:
STREET 1: THE CIRCLE 6
STREET 2: 8058
CITY: ZURICH
STATE: V8
ZIP: CH-6370
D
1
primary_doc.xml
X0708
D
LIVE
0001783036
NLS Pharmaceutics Ltd.
THE CIRCLE 6
ZURICH
V8
SWITZERLAND
CH-8058
+41.44.512.2150
SWITZERLAND
None
None
Other
Limited Company
true
Alexander
Zwyer
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Executive Officer
Director
Chief Executive Officer
Ronald
Hafner
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Director
Eric
Konofal
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Executive Officer
Chief Scientific Officer and Interim Chief Medical Officer
Elena
Thyen-Pighin
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Executive Officer
Chief Financial Officer
Gian-Marco
Rinaldi
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Director
Audrey
Greenberg
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Director
Claudio
L.A.
Basseti
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Director
Florence
Allouche
Aknin
The Circle 6
Zurich
V8
SWITZERLAND
CH-8058
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2024-06-28
false
true
true
true
false
0
H.C. Wainwright & Co., LLC
000000375
None
None
430 Park Ave
3rd Floor
New York
NY
NEW YORK
10022
NY
NEW YORK
false
786660
786660
0
Represents total gross proceeds received by the company in connection with a concurrent registered directoffering of common shares and concurrent private placement of warrants to purchase common shares.
false
2
62933
0
H.C. Wainwright & Co., LLC ("Wainwright") acted as the placement agent in connection with the offering. Wainwright received an aggregate fee equal to 8.0% of the gross proceeds raised in the offering and warrants to purchase up to 229,443 common shares.
0
false
NLS Pharmaceutics Ltd.
/s/ Alexander Zwyer
Alexander Zwyer
Chief Executive Officer
2024-07-12